Recombinant Human TRAIL R2/TNFRSF10B Fc Chimera Protein, CF

Recombinant Human TRAIL R2/TNFRSF10B Fc Chimera (Catalog #10140-T2) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) mediated cytotoxicity using L‑929 mouse fibroblast cells. TheED50 for this effect is 0.75‑6 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TRAIL R2/TNFRSF10B Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED₅₀ for this effect is 0.75-6 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human TRAIL R2/TNFRSF10B protein
  

  Human TRAIL R2/TNFRSF10B (Ala54-Ser210) Accession # AAH01281.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAH01281.1
• N-terminal Sequence: Ala54
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 54-61 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TRAIL R2/TNFRSF10B Fc Chimera Protein, CF

• CD262 antigen
• CD262
• death domain containing receptor for TRAIL/Apo-2L
• Death receptor 5
• DR5
• DR5TRICK2B
• Fas-like protein
• KILLER/DR5
• KILLERapoptosis inducing protein TRICK2A/2B
• TNF-related apoptosis-inducing ligand receptor 2
• TNFRSF10B
• TRAIL R2
• TRAIL receptor 2
• TRAILR2
• TRAIL-R2apoptosis inducing receptor TRAIL-R2
• TRAILR2cytotoxic TRAIL receptor-2
• TRICK2
• TRICK2A
• TRICKB
• tumor necrosis factor receptor superfamily member 10B
• tumor necrosis factor receptor superfamily, member 10b
• tumor necrosis factor receptor-like protein ZTNFR9
• ZTNFR9

Background

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand) (1). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. There are no known rat or mouse homologs to TRAILR2. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis (1-2). The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis (1-2). Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported (3).

1. Chaudhary, P.M. et al. (1997) Immunity 7:821.
2. Walczak, H. et al. (1997) EMBO J. 16:5386.
3. Golstein, P. (1997) Curr. Biol. 7:R750.

Publications for TRAILR2/TNFRSF10B (10140-T2)(3)

Publications using 10140-T2

• AV Yagolovich, AA Isakova, AA Artykov, YV Vorontsova, DV Mazur, NV Antipova, MS Pavlyukov, MI Shakhparon, AM Gileva, EA Markvichev, EA Plotnikova, AA Pankratov, MP Kirpichnik, ME Gasparian, DA Dolgikh DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma International Journal of Molecular Sciences, 2022-10-21;23(20):. 2022-10-21 [PMID: 36293545] (ELISA Capture, Human)
• MW Lee, DS Kim, JE Eom, JW Lee, KW Sung, HH Koo, YB Hong, KH Yoo Dual role of ERK2/NF-kappaB signaling in TRAIL sensitivity American journal of cancer research, 2022-07-15;12(7):3373-3389. 2022-07-15 [PMID: 35968322] (Cell Culture, Human)
• S Natesampil, AC Paim, NW Cummins, AP Chandrasek, GD Bren, SR Lewin, HP Kiem, AD Badley TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection J. Immunol., 2019-06-12;0(0):. 2019-06-12 [PMID: 31189571] (Immunoprecipitation, Human)

Bioinformatics

• Uniprot:
  • AAH01281.1()